- Two (02) New client wins for Aagami.
- Aagami also won contract extensions from Three (03) existing clients.
- Aagami successfully completed 45+ One-on-One partnering meetings in BIO International Convention 2022 in San Diego, while also representing multiple clients.
INFOCUS: Select opportunities available at Aagami:
US FDA & DEA approved facilities in US for API & formulations
for use via contract manufacturing/leasing
These facilities host manufacturing & development capabilities in
controlled substance APIs & formulations. If you would like to know more details for engaging/utilizing these
facilities, please contact us.
For Acquisition: 1. Mountain View Pharma (MVP) including its PharmaPEG® technology,
product candidates, data package of ~20 drug candidates, IP etc.- for
Next-generation biologics and substantial returns. Available at a very
reasonable price. For Partnering/Licensing/ Investment: - Investment Licensing - US FDA approved portable MRI Guided Treatment, Diagnosis
and Screening ($40 Million Series C Open). For Urology applications.
- Licensing, Co-development - 505(b)(2) low cost near market IP protected
Bendamustine. Can be brought to market in 2024 without any infringement.
Negligible competition (3) at the moment. Good market share potential.
- Licensing/Strategic Partnership: Next-gen AI powered imaging to pinpoint the
IVF +/- 12 hour window of opportunity to implant the embryo. First solution
that supports the science of uterine receptivity vs. a physician's estimates or
inaccurate ultrasound. Market Launch early 2024.
- Series B Open- Novel Evolution of Portable MRI and Robotics
for Neurology treatments like Strokes and TBI.
- Technology Licensing: Easy to apply Microneedle Array Patch (MAP)
system to deliver drugs, vaccines; better immune response than injection.
A painless and efficient replacement to Syringes.
- Midwest US based Pharma’s First-in-Class
Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking
funding/licensing/co-development partnerships.
|